| Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial PB Panici, S Basile, F Maneschi, AA Lissoni, M Signorelli, G Scambia, ... JNCI: Journal of the National Cancer Institute 100 (23), 1707-1716, 2008 | 1945 | 2008 |
| Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial PB Panici, A Maggioni, N Hacker, F Landoni, S Ackermann, ... Journal of the National Cancer Institute 97 (8), 560-566, 2005 | 640 | 2005 |
| Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study P Benedetti-Panici, S Greggi, A Colombo, M Amoroso, D Smaniotto, ... Journal of Clinical Oncology 20 (1), 179-188, 2002 | 609 | 2002 |
| Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in … L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Caliò, ... PloS one 10 (6), e0130142, 2015 | 535 | 2015 |
| Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial L Calabrò, A Morra, E Fonsatti, O Cutaia, G Amato, D Giannarelli, ... The Lancet Oncology 14 (11), 1104-1111, 2013 | 436 | 2013 |
| Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ... Annals of Oncology 27 (4), 732-738, 2016 | 428 | 2016 |
| Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab M Capone, D Giannarelli, D Mallardo, G Madonna, L Festino, AM Grimaldi, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 423 | 2018 |
| Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy AM Grimaldi, E Simeone, D Giannarelli, P Muto, S Falivene, V Borzillo, ... Oncoimmunology 3 (5), e28780, 2014 | 415 | 2014 |
| Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features FR Mauro, R Foa, R Cerretti, D Giannarelli, S Coluzzi, F Mandelli, G Girelli Blood, The Journal of the American Society of Hematology 95 (9), 2786-2792, 2000 | 388 | 2000 |
| Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases FR Mauro, R Foa, D Giannarelli, I Cordone, S Crescenzi, E Pescarmona, ... Blood, The Journal of the American Society of Hematology 94 (2), 448-454, 1999 | 339 | 1999 |
| Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response A Pace, A Vidiri, E Galie, M Carosi, S Telera, AM Cianciulli, P Canalini, ... Annals of Oncology 14 (12), 1722-1726, 2003 | 329 | 2003 |
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial AM Di Giacomo, PA Ascierto, L Pilla, M Santinami, PF Ferrucci, ... The lancet oncology 13 (9), 879-886, 2012 | 306 | 2012 |
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Caracò, ... Cancer immunology, immunotherapy 63, 675-683, 2014 | 285 | 2014 |
| Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial A Pace, D Giannarelli, E Galie, A Savarese, S Carpano, M Della Giulia, ... Neurology 74 (9), 762-766, 2010 | 259 | 2010 |
| Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian … F Cognetti, EM Ruggeri, A Felici, M Gallucci, G Muto, CF Pollera, ... Annals of oncology 23 (3), 695-700, 2012 | 258 | 2012 |
| Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients PF Ferrucci, S Gandini, A Battaglia, S Alfieri, AM Di Giacomo, ... British journal of cancer 112 (12), 1904-1910, 2015 | 244 | 2015 |
| Clinical Significance of αvβ3 Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions PG Natali, CV Hamby, B Felding-Habermann, B Liang, MR Nicotra, ... Cancer Research 57 (8), 1554-1560, 1997 | 237 | 1997 |
| Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study L Calabrò, A Morra, E Fonsatti, O Cutaia, C Fazio, D Annesi, M Lenoci, ... The Lancet Respiratory Medicine 3 (4), 301-309, 2015 | 235 | 2015 |
| Can patient selection for bladder preservation be based on response to chemotherapy? CN Sternberg, V Pansadoro, F Calabrò, S Schnetzer, D Giannarelli, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 235 | 2003 |
| Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study L Calabrò, A Morra, D Giannarelli, G Amato, A D'Incecco, A Covre, ... The Lancet Respiratory Medicine 6 (6), 451-460, 2018 | 231 | 2018 |
Francesco CognettiDirettore Oncologia Medica 1 IFO Istituto Nazionale Tumori Regina Elena RomaVerifisert e-postadresse på ifo.it
